Skip to main content
. 2023 Jul 31;15(15):3901. doi: 10.3390/cancers15153901

Figure 2.

Figure 2

Hurdles to successful immunotherapy in rGBM. The blood–brain barrier (BBB), glioma heterogeneity, glioma-associated microglia/myeloid cells, and T cell suppression are established features in GBM that are anticipated to resist immunotherapy. See Section 3.6 for discussion. MDSCs = Myeloid Derived Suppressor Cells, PMN—polymorphonuclear leukocytes, MGMT = O-6-mehtyguanine-DNA methyltransferase; CAR = Chimeric Antigen Receptor.